Risk assessment behaviour: Evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test

Pharmacology Biochemistry and Behavior

Volumn 57, Issue 4, 1997, Pages 817-827

  Griebel, Guy ^c   Rodgers, R John ^b   Perrault, Ghislaine ^a   Sanger, David J ^a  

^a SANOFI   (France)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c NONE

Author keywords

5 HT interacting drugs; Anxiety; Elevated plus maze; Rat; Risk assessment

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ANXIOLYTIC AGENT; BEMESETRON; BUSPIRONE; FLESINOXAN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; IPSAPIRONE; KETANSERIN; MIANSERIN; ONDANSETRON; PARTIAL AGONIST; PIRENPERONE; RITANSERIN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TROPISETRON; ZACOPRIDE; ZIMELDINE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; ETHOLOGY; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; SEROTONINERGIC SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTI-ANXIETY AGENTS; LIGANDS; MALE; MAZE LEARNING; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RISK-TAKING; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

ANIMALIA;

EID: 0030813322     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(96)00402-9     Document Type: Article

References (50)

1. Blanchard, D. C.; Blanchard, R. J.; Tom, P.; Rodgers, R. J.: Diaz-epam changes risk assessment in an anxiety/defense test battery. Psychopharmacology 101:511-518; 1990.
2. Blanchard, D. C.; Shepherd, J. K.; Rodgers, R. J.; Blanchard, R. J.: Evidence for differential effects of 8-OH-DPAT on male and female rats in the anxiety/defense test battery. Psychopharmacology 106:531-539; 1992.
3. 2 dopamine receptors in buspirone effects on cortical electrical activity in rats. Neurosci. Lett. 177:1-4; 1994.
4. Brady, L. S.; Barrett, J. E.: Effects of serotonin receptor antagonists on punished responding maintained by stimulus-shock termination or food presentation in squirrel monkeys. J. Pharmacol. Exp. Ther. 234:106-112; 1985.
5. Cole, B. J.; Hillmann, M.; Seidelmann, D.; Kiewer, M.; Jones, G. H.: Effects of benzodiazepine receptor partial inverse agonists in the elevated plus maze test of anxiety in the rat. Psychopharmacology 121:118-126; 1995.
6. Cole, J. C.; Rodgers, R. J.: An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze. Behav. Pharmacol. 4:573-580; 1993.
7. Cole, J. C.; Rodgers, R. J.: Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: Comparison with haloperidol. Psychopharmacology 114:288-296; 1994.
8. Cruz, A. P. M.; Frei, F.; Graeff, F. G.: Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol. Biochem. Behav. 49:171-176; 1994.
9. Dawson, G. R.; Tricklebank, M. D.: Use of the elevated plus maze in the search for novel anxiolytic agents. Trends Pharmacol. Sci. 16:33-36; 1995.
10. Goldberg, H. L.: Buspirone - A new antianxiety agent not chemically related to any presently marketed drugs [proceedings]. Psychopharmacol. Bull. 15:90-92; 1979.
11. Gonzalez, M. I.; Farabollini, F.; Albonetti, E.; Wilson, C. A.: Interactions between 5-hydroxytryptamine (5-HT) and testosterone in the control of sexual and nonsexual behaviour in male and female rats. Pharmacol. Biochem. Behav. 47:591-601; 1994.
12. 3H-PAT. Nature 305:140-142; 1983.
13. Green, S.: Benzodiazepines, putative anxiolytics and animal models of anxiety. Trends Neurosci. 14:101-104; 1991.
14. Griebel, G.: Système sérotoninergique et réactivité émotionnelle chez le rat et chez la souris. Approche pharmacologique. Strasbourg, France: Université Louis Pasteur; 1993.
15. Griebel, G.: 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research. Pharmacol. Ther. 65:319-395; 1995.
16. Griebel, G.; Blanchard, D. C.; Jung, A.; Blanchard, R. J.: A model of 'antipredator' defense in Swiss-Webster mice: Effects of benzodiazepine receptor ligands with different intrinsic activities. Behav. Pharmacol. 6:732-745; 1995.
17. 2A antagonist pirenperone. Pharmacol. Biochem. Behav. 51:235-244; 1995.
18. Griebel, G.; Sanger, D. J.; Perrault, G.: The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands. Psychopharmacology 124:245-254; 1996.
19. Handley, S. L.: 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol. Ther. 66:103-148; 1995.
20. Hjorth, S.; Carlsson, A.: Buspirone: Effects on central monoaminergic transmission - Possible relevance to animal experimental and clinical findings. Eur. J. Pharmacol. 83:299-303; 1982.
21. Hoyer, D.; Clarke, D. E.; Fozard, J. R.; Hartig, P. R.; Martin, G. R.; Mylecharane, E. J.; Saxena, P. R.; Humphrey, P. P. A., VII: International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46:157-204; 1994.
22. 1C receptor antagonists have anxiolytic-like actions in the rat social interaction model. Psychopharmacology 107:379-384; 1992.
23. Mason, P.; Skinner, J.; Luttinger, D.: Two tests in rats for antianxiety effect of clinically anxiety attenuating antidepressants. Psychopharmacology 92:30-34; 1987.
24. 1C/2 antagonists, potential anxiolytic agents. In: Hamon, M.; Ollat, H.; Thiebot, M. H., eds. Anxiety: Neurobiology, clinic and therapeutic perspectives. Paris: Les Editions INSERM/John Libbey Eurotext; 1993:153-164.
25. Molewijk, H. E.; Vanderpoel, A. M.; Olivier, B.: The ambivalent behaviour "stretched approach posture" in the rat as a paradigm to characterize anxiolytic drugs. Psychopharmacology 121:81-90; 1995.
26. Moser, P. C.: An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone. Psychopharmacology 99:48-53; 1989.
27. Pellow, S.; Chopin, P.; File, S. E.; Briley, M.: Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14:149-167; 1985.
28. Pellow, S.; Johnston, A. L.; File, S. E.: Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes, and interactions with yohimbine and FG 7142 using the elevated plus-maze test in the rat. J. Pharm. Pharmacol. 39:917-928; 1987.
29. Rickels, K.; Weisman, K.; Norstad, N.; Singer, M.; Stoltz, D.; Brown, A.; Danton, J.: Buspirone and diazepam in anxiety: A controlled study. J. Clin. Psychiatry 43:81-86; 1982.
30. Rodgers, R. J.: A step in the right direction: Comment on "5-HT and mechanisms of defence." J. Psychopharmacol. 5:316-319; 1991.
31. 1A receptor antagonist, in the murine elevated plus-maze test. Eur. J. Pharmacol. 261:321-325; 1994.
32. Rodgers, R. J.; Cole, J. C.: The elevated plus-maze: Pharmacology, methodology and ethology. In: Cooper, S. J.; Hendrie, C. A., eds. Ethology and psychopharmacology. Chichester, UK: John Wiley & Sons Ltd.; 1994:9-44.
33. Rodgers, R. J.; Cole, J. C.; Cobain, M. R.; Daly, P.: Anxiogenic-like effects of fluprazine and eltoprazine in the mouse elevated plus-maze: Profile comparisons with 8-OH-DPAT, CGS 12066B, TFMPP and mCPP. Behav. Pharmacol. 3:621-634; 1992.
34. 1A receptor agonist, flesinoxan. Pharmacol. Biochem. Behav. 48:959-963; 1994.
35. 3 receptor antagonists, ondansetron and WAY 100289, in the elevated plus-maze test of anxiety of mice. Psychopharmacology 117: 306-312; 1995.
36. Rodgers, R. J.; Johnson, N. J. T.: Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 52:297-303; 1995.
37. Rodgers, R. J.; Johnson, N. J. T.; Norton, S. J.; Cole, J. C.: Effects of ritanserin and 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) in the murine elevated plus-maze test of anxiety: An ethopharmacological study. J. Psychopharmacol. 9:38-42; 1995.
38. 1A receptor ligands in animal models of anxiety, impulsivity and depression: Multiple mechanisms of action? Prog. Neuropsychopharmacol. Biol. Psychiatry 17:87-104;1993.
39. 1A receptor agonists 8-OH-DPAT, ipsapirone and buspirone in the rat. Eur. J. Pharmacol. 249:341-351; 1993.
40. Shepherd, J. K.; Grewal, S. S.; Fletcher, A.; Bill, D. J.; Dourish, C. T.: Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psycho-pharmacology 116:56-64; 1994.
41. 1A receptor agonists and L-5-HTP in Montgomery's conflict test. Pharmacol. Biochem. Behav. 32:259-265; 1989.
42. Stutzmann, J. M.; Eon, B.; Darche, F.; Lucas, M.; Rataud, J.; Piot, O.; Blanchard, J. C.; Laduron, P. M.: Are 5-HT2 antagonists endowed with anxiolytic properties in rodents? Neurosci. Lett. 128:4-8; 1991.
43. Sullivan, J. W.; Gold, L.; Sepinwall, J.: Anticonflict effects of three compounds having antiserotonergic activity: Metergoline, minaserin, and clozapine. Soc. Neurosci. Abstr. 11:1187; 1985.
44. Taylor, D. P.; Riblet, L. A.; Stanton, H. C.; Eison, A. S.; Eison, M. S.; Temple, D. L.: Dopamine and antianxiety activity. Pharmacol. Biochem. Behav. 17(suppl. 1):25-35; 1982.
45. Tomkins, D. M.; Costall, B.; Kelly, M. E.: Action of ritanserin and DOI on the elevated X-maze. Psychopharmacology 101:857; 1990.
46. 3 antagonists and benzodiazepines. Their comparative behavioural pharmacology. Chichester, UK: John Wiley & Sons; 1991:107-131.
47. Treit, D.; Menard, J.; Royan, C.: Anxiogenic stimuli in the elevated plus-maze. Pharmacol. Biochem. Behav. 44:463-469; 1993.
48. 1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propyl-amino)tetralin in the rat. Eur. J. Pharmacol. 106:271-282; 1984.
49. Witkin, J. M.; Perez, L. A.: Comparison of effects of buspirone and gepirone with benzodiazepines and antagonists of dopamine and serotonin receptors on punished behavior of rats. Behav. Pharmacol. 1:247-254; 1990.
50. Wright, I. K.; Heaton, M.; Upton, N.; Marsden, C. A.: Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze. Psychopharmacology 107:405-414; 1992.